Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      AmyriAD Therapeutics Acquires AD04 Alzheimer's Program from ADvantage, Further Expanding Its Clinical-Stage Cognition Pipeline

      AmyriAD Logo

      News provided by

      AmyriAD Therapeutics

      Nov 16, 2026, 08:42 ET

      Share this article

      Share this article


      Phase 2b-ready program targeting neuroinflammation in mild Alzheimer's disease complements lead program Ismidenon in moderate Alzheimer's

      AMSTERDAM, Nov. 16, 2026 /PRNewswire/ -- AmyriAD Therapeutics B.V. ("AmyriAD"), a clinical-stage biopharmaceutical company developing therapies that address biological drivers of cognitive decline, today announced the acquisition of the AD04 Alzheimer's disease program and related assets from ADvantage Therapeutics, Inc. ("ADvantage"). The acquisition adds a Phase 2b-ready program targeting neuroinflammation in mild Alzheimer's disease, complementing AmyriAD's lead program, Ismidenon, in moderate Alzheimer's.

      AD04 is an investigational drug subcutaneously administered. Its mechanism of action is initiated by peripheral inflammation and results in inflammation resolution in the brain and the elimination of waste, including lipid microdroplets.

      Strategic Rationale

      "Cognitive decline threatens people's independence, relationships and daily lives. Addressing it requires more treatment options across different biological mechanisms and stages of disease," said K. Ranga Rama Krishnan, Chairman of the Board and CEO of AmyriAD. "Following our acquisition of Recognify Life Sciences, AD04 further expands our cognition pipeline alongside lead program Ismidenon. We are building this portfolio with a clear purpose: helping people preserve the abilities that make life their own."

      "AD04's clinical findings provide a compelling foundation for its continued development in mild Alzheimer's disease," said Jeffrey B. Madden, Chief Executive Officer of ADvantage Therapeutics. "I'm excited to combine our experience with AD04 and AmyriAD's expertise in cognition as we advance toward Phase 2b, building on the program's Innovation Passport under the United Kingdom's Innovative Licensing and Access Pathway (ILAP)."

      AD04's clinical rationale emerged from AFF006, a 332-patient Phase 2 Alzheimer's vaccine study. In this study, AD04 served as a control treatment. AD04 is based on a proprietary formulation of aluminum hydroxide hydrogel with a specific dosage. Exploratory post hoc analyses of patients who received AD04 identified signals of slower cognitive decline and reduced hippocampal volume loss.

      Development Plan

      AmyriAD intends to advance AD04 into Phase 2b development in mild Alzheimer's disease to prospectively evaluate its safety and efficacy. The program has received an Innovation Passport under the United Kingdom's Innovative Licensing and Access Pathway.

      Transaction Details

      Under the terms of the agreement, AmyriAD acquired worldwide rights to AD04, including associated intellectual property, clinical data and regulatory assets.

      Jeffrey B. Madden and members of ADvantage's clinical and scientific team will continue to support AD04 in advisory roles, providing continuity and program expertise as AmyriAD advances development.

      About AD04

      AD04 is an investigational drug, subcutaneously administered, based on an aluminum hydroxide hydrogel, with a specific and proprietary dosage. Its proposed mechanism targets immune processes relevant to neuroinflammation.

      About Ismidenon (AD-101)

      Ismidenon (AD-101) is AmyriAD's lead investigational program, being developed as an oral add-on symptomatic treatment for cognitive impairment in moderate Alzheimer's disease. It targets presynaptic T-type calcium channels to increase acetylcholine release. Studied in more than 500 patients, Ismidenon is moving to a Phase 2 study.

      About RL-007 (Inidascamine)

      RL-007 is an investigational oral small molecule being developed for cognitive impairment. It modulates cholinergic, glutamatergic and gamma-aminobutyric acid type B (GABA-B) receptor signaling and has completed Phase 2a and Phase 2b studies in cognitive impairment associated with schizophrenia. AmyriAD plans extended-release formulation development and a pharmacokinetic study to guide further development.

      About AmyriAD Therapeutics

      AmyriAD Therapeutics B.V. is a clinical-stage biopharmaceutical company developing therapies targeting biological drivers of cognitive decline. Anchored by lead program Ismidenon (AD-101), AmyriAD is building a portfolio of complementary programs across biological mechanisms and stages of cognitive decline, each with its own clinical development path. AmyriAD is headquartered in Amsterdam, the Netherlands. Visit www.amyriadtherapeutics.com.

      Forward-Looking Statements

      This release contains forward-looking statements regarding the acquisition's anticipated benefits and planned clinical development. Actual results may differ materially due to clinical, regulatory, financing and other drug-development risks. Earlier findings may not be replicated. AmyriAD undertakes no obligation to update these statements except as required by law.

      Contacts

      Kim Bruin, [email protected] (Investors)

      Ankil Patel, 917-561-6464, [email protected] (Media)

      SOURCE AmyriAD Therapeutics

      Modal title

      Also from this source

      AmyriAD Therapeutics Acquires Recognify Life Sciences, Expanding Its Clinical-Stage Cognition Pipeline with RL-007 (Inidascamine)

      AmyriAD Therapeutics Acquires Recognify Life Sciences, Expanding Its Clinical-Stage Cognition Pipeline with RL-007 (Inidascamine)

      AmyriAD Therapeutics B.V. ("AmyriAD"), a clinical-stage biopharmaceutical company focused on cognition in central nervous system disorders, today...

      More Releases From This Source

      Explore

      Medical Pharmaceuticals

      Medical Pharmaceuticals

      Health Care & Hospitals

      Health Care & Hospitals

      Biotechnology

      Biotechnology

      Pharmaceuticals

      Pharmaceuticals

      News Releases in Similar Topics

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.